The pairing is described in the literature as a way to stimulate growth hormone through two complementary pathways that converge on the somatotroph cells of the anterior pituitary, producing a larger and more physiologically shaped pulse than either compound reportedly delivers alone. CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that raises the releasable pool, while Ipamorelin is a selective secretagogue that triggers the actual pulse, so the two are characterized as acting synergistically rather than additively. Neither peptide is FDA-approved for general human therapeutic use; both are sold as research-use-only compounds, and most of what is reported on the combination comes from preclinical work, limited early-phase studies, and practitioner observation rather than large controlled trials.
CJC-1295 and Ipamorelin are paired because one is reported to raise the releasable growth hormone pool through the GHRH receptor while the other triggers its release through the ghrelin receptor, an interaction the literature characterizes as synergistic rather than additive, and neither is FDA-approved for human therapeutic use.
The two peptides are documented as acting on entirely different receptors, which is the structural reason the literature treats them as distinct rather than redundant. CJC-1295, a modified analog of the first twenty-nine amino acids of GHRH, is reported to bind the GHRH receptor and signal through the cyclic AMP pathway to increase both the synthesis and the releasable store of growth hormone; Ipamorelin instead binds the growth hormone secretagogue receptor (GHSR-1a), the same receptor ghrelin targets, and acts through a phospholipase C and intracellular calcium pathway to evoke the actual release. One framing in the literature is that the GHRH analog governs how much hormone the pituitary prepares while the ghrelin mimetic governs when it is released.
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor | GHRH receptor | GHSR-1a (ghrelin receptor) |
| Signaling pathway | Cyclic AMP | Phospholipase C / intracellular calcium |
| Reported function | Primes and enlarges the releasable GH store | Triggers exocytosis of GH |
| Somatostatin effect | None described as direct | Reported to blunt somatostatin tone |
CJC-1295 is documented as binding the GHRH receptor through the cyclic AMP pathway to enlarge the releasable growth hormone store, whereas Ipamorelin binds the GHSR-1a receptor through a calcium pathway to trigger release, so only Ipamorelin is described as a secretagogue in the strict sense.
Synergy in this pairing is reported to mean the combined response exceeds the simple sum of the two peptides given separately, with the explanation resting on how the two signals interact at the somatotroph. The literature describes a supra-additive release in which the combined peak is larger than the arithmetic total of the individual peaks, an effect generally attributed to convergence of the cyclic AMP and calcium signaling pathways within the same cell. This combined mechanism is the central pharmacological argument practitioners cite for using the two together rather than either in isolation.
Studies of GHRH and ghrelin-receptor agonists used together are reported to show a supra-additive growth hormone release, where the combined peak exceeds the arithmetic sum of the individual peaks, attributed to convergence of the cyclic AMP and calcium pathways within the same somatotroph.
Ipamorelin is documented as favored chiefly for its selectivity, releasing growth hormone with very little of the collateral hormonal disturbance reported for earlier members of the ghrelin-mimetic class. The first-generation growth hormone releasing peptides, GHRP-6 and GHRP-2, are described as effective at stimulating growth hormone but as also raising cortisol and prolactin, with GHRP-6 producing pronounced appetite stimulation through its ghrelin-like activity. Ipamorelin was developed to retain potent release while minimizing those off-target effects, and the published record frequently characterizes it as the first secretagogue with selectivity approaching that of GHRH itself.
| Criterion | Ipamorelin | GHRP-6 | GHRP-2 |
|---|---|---|---|
| Cortisol effect | Negligible at research doses | Raised | Raised |
| Prolactin effect | Negligible at research doses | Raised | Raised |
| Appetite stimulation | Minimal | Pronounced | Moderate |
| Reported selectivity | Approaching that of GHRH | Lower | Lower |
Ipamorelin is documented as the secretagogue of choice in this pairing because it is reported to produce negligible elevations in cortisol and prolactin at standard research doses, where earlier ghrelin mimetics GHRP-6 and GHRP-2 raise both and GHRP-6 also markedly stimulates appetite.
The dosing logic reported in the literature depends heavily on which form of CJC-1295 is used, because the name covers two pharmacokinetically different molecules. Ipamorelin is short-acting, with a half-life on the order of about two hours, so research protocols are described as administering it in discrete doses to evoke a fresh pulse each time. Because endogenous growth hormone release is largest during deep sleep and elevated blood glucose is reported to blunt secretion, administration is frequently discussed in the literature in relation to bedtime and fasted states.
Ipamorelin carries a half-life of about two hours, the no-DAC form of CJC-1295 clears in roughly thirty minutes and is reportedly co-injected with it, while the DAC-modified form persists for roughly six to eight days and is documented as a once- or twice-weekly injection layered with more frequent Ipamorelin dosing.
Preserving pulsatility is documented as one of the central conceptual arguments for stimulating the pituitary rather than supplying growth hormone from outside the body. Endogenous growth hormone is reported to be released in bursts, with the largest pulses during slow-wave sleep, and the responding tissues appear tuned to this on-and-off pattern rather than to continuous exposure. Because CJC-1295 and Ipamorelin prompt the gland to release its own stored hormone, the timing, magnitude, and shape of each pulse are described as remaining under the control of the pituitary and its feedback loops.
Because CJC-1295 and Ipamorelin act by prompting the pituitary to release its own stored growth hormone, the timing and magnitude of each pulse are documented as remaining under the gland's feedback control, in contrast to recombinant growth hormone, which imposes a flat externally determined level.
The safety argument in the literature rests largely on selectivity and on the indirect mechanism of release, but it is documented as needing to be weighed against substantial gaps in long-term human evidence. Because Ipamorelin is reported to release growth hormone with minimal effect on cortisol, prolactin, and aldosterone, the pairing is described as avoiding much of the broad endocrine disruption associated with older secretagogues. That framing does not eliminate the underlying risks of elevating growth hormone and IGF-1, and the most important caveat is that neither peptide is approved for general human therapeutic use, with no large, long-duration controlled trials of the combination.
The selectivity case for the combination does not eliminate the documented risks of sustained growth hormone and IGF-1 elevation, including insulin resistance, fluid retention, joint discomfort, and a theoretical concern about promoting existing neoplastic tissue, and no large, long-duration controlled trials of the pairing exist.
Neither CJC-1295 nor Ipamorelin is documented as holding FDA approval as a drug for any general human therapeutic indication, and there is no approved product that combines the two. Both are reported as sold and distributed as research peptides, typically labeled for laboratory or research use only, a designation meaning they have not undergone the clinical trial and review process required for medicines. The thin evidence base is itself described as a consequence of this status, since without an approved indication there is little incentive to fund the large controlled trials that would establish efficacy and safety.
Neither CJC-1295 nor Ipamorelin holds FDA approval for any human therapeutic indication and no combination product exists; both are distributed as research-use-only compounds, appear on the World Anti-Doping Agency prohibited list, and have been placed outside the bulk substances compounding pharmacies may use.
Educational use only. This article describes what the published scientific and clinical literature reports about CJC-1295 and Ipamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
